Coya Therapeutics (COYA) investor relations material

Investment highlights and market opportunity

• Targeting ALS, FTD, and Alzheimer's with high unmet need and regulatory flexibility.

• COYA 302 and COYA 303 use novel Treg-directed combination therapies.

• COYA 302 Phase 2 ALS study ongoing; FTD Phase 2 to start in 2026.

• Pipeline potential exceeds $10B across ALS, FTD, AD, and PD.

• Strong partnerships, including Dr. Reddy's with up to $700M in milestones and $47M cash runway into 2H 2027.

Scientific rationale and therapeutic approach

• Combination therapies restore Treg function, reduce neuroinflammation, and improve clinical outcomes.

• Low-dose IL-2 and CTLA4-Ig synergistically expand and enhance Tregs.

• Treg dysfunction is linked to neurodegeneration; restoring balance may slow disease progression.

• Early clinical data show stabilization or improvement in ALS and FTD patients.

• Nobel Prize-recognized science underpins the approach.

Clinical development and trial updates

• COYA 302 ALSTARS Phase 2 ALS trial is enrolling; top-line data expected 1Q 2027.

• COYA 302 FTD Phase 2a to initiate 2H 2026; primary endpoint is safety and tolerability.

• Investigator-initiated trials show improved or stable ALSFRS-R scores and cognitive stability in FTD.

• COYA 303 for Alzheimer's combines LD IL-2 with GLP-1 RA; preclinical data show reduced neuroinflammation.

• IND for COYA 303 accepted 1Q 2026; pre-IND meeting with FDA mid-2026.